An observational study in Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis, sponsored by University Hospital, Brest. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2024-08-12.
Sponsored by University Hospital, Brest · Observational
All patients diagnosed or followed in Brest University Hospital for Philadelphia negative myeloproliferative neoplasms will be included in this observational study.
Myeloproliferative neoplasms recorded included: polycythemia vera, essential Thrombocythemia and Primary Myelofibrosis.
This is a not interventional study. Alive patients need to sign a non-opposition consent form.
Patients will be followed until last news (death, change of reference centre...).
In this retrospective and prospective study, clinical and biological data from diagnosis until last news will be recorded.
Clinical data collected: patients and disease characteristics at the time of the diagnosis, disease and mutational status, cardio-vascular risk factors, history of thrombosis and cancer.
Biological data collected: hemogram and bone marrow results if available. During the follow-up new data will be noted: treatment changes (reasons of change and type of drug), thrombotic events (localization, date and hemogram), phenotypic evolutions (type and date), death (date and etiology).
278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 240 across 44 observational studies indexed under Polycythemia Vera.
Browse Polycythemia Vera studies →University Hospital, Brest is the lead sponsor of 601 studies on the registry; 136 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients followed for essentiel thrombocythemia, polycythemia vera or primary myelofibrosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Overall Survival
occurrence of death
Time frame: 10 years
Incidence of evolutions
occurrence of transformation into polycythemia vera, secondary myelofibrosis, myelodysplastic syndrome or acute leukemia
Time frame: 10 years
Incidence of thromboses
occurrence of arterial or venous thrombotic events
Time frame: 10 years
Plan to share: No
Started Sep 2015 (actual). Primary completion is estimated for Sep 2025, 120 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.